AI/ML News & Innovations Hub

Build an agentic AI healthcare claims pipeline with Amazon Bedrock and AWS HealthLake

In this post, we show you how to build an automated claims processing pipeline using two key Amazon Bedrock capabilities: Amazon Bedrock Data Automation for intelligent document extraction from healthcare claim forms, and Amazon Bedrock AgentCore for hosting an AI agent that validates and transforms the extracted data into FHIR (Fast Healthcare Interoperable Resources) resources in AWS HealthLake. You will learn how to combine these services to create an end-to-end workflow that reduces manual processing while maintaining accuracy through automated validation checks.

A Soweto startup’s unlikely journey from gadgets to AI healthcare

Founded in Soweto and backed largely with internally generated revenue and founder reinvestment, Khoi Tech initially built its reputation through consumer devices such as the Khoi Afripods true wireless earphones and the Khoi Afriwatch1 smartwatch.

Exclusive: JiviAI shuts down; founder Ankur Jain may rejoin BharatPe

JiviAI, an AI healthcare startup founded by former BharatPe Chief Product Officer Ankur Jain, has shut down operations, according to multiple sources familiar with the matter. The development comes less than two years after the startup entered the crowded generative AI healthcare space. The company had bet on proprietary AI models to deliver medical assistance and healthcare related services. The startup also raised an undisclosed funding in late 2024. According to sources, the shutdown came amid rising infrastructure costs, funding challenges, and failed acquisition discussions. “Building and running proprietary AI models became increasingly expensive. When you’re up against companies like OpenAI and Google, it becomes very difficult to make the economics work,” said a person familiar with the matter, requesting anonymity. According to another source, investors who had initially shown interest in backing the company did not participate in its planned funding round, putting additional pressure on its finances. “There were a few acquisition discussions as well, but none of them materialised. Once those fell through, the company had very few options left,” the person said. Sources said employees have been informed about the shutdown and have been asked to leave as the company winds down operations. Industry sources also suggest that Jain is evaluating his next move. Some industry observers have speculated about a possible return to BharatPe following the recent departure of Gr…

Healthcare Benchmarks Are Only as Good as Their Assumptions

In healthcare settings where patients use LLMs as a medical assistant, LLM performance differs between evaluation and deployment. (a) Bean et al. (2025) find a 61 percentage point difference between evaluation and deployment. (b) We argue this gap arises not from poorly designed benchmarks, but from implicit assumptions embedded in evaluation protocols that fail to hold at deployment. (c) We propose a taxonomy that categorizes assumptions into two types, task and outcome, to diagnose where the gap arises and what is required to close it. Closing the gap requires making assumptions explicit, testing which assumptions hold, and updating evaluation protocols accordingly. Healthcare LLM benchmarks are one of the main paradigms by which LLMs are evaluated prior to clinical settings. Benchmarks provide a stable goalpost that allow researchers to iterate quickly and measure progress consistently. However, in high-stakes domains like healthcare, that same abstraction becomes a liability. For example, a recent study found a 61 percentage point drop in accuracy when going from evaluation to deployment (see Figure). In this setting, patients use LLMs as a medical assistant to better understand their symptoms, identify the underlying condition, and take appropriate actions. Moreover, the results showed that patients given access to a […]

How a Google DeepMind Spin-off Hunts Hidden Drug Targets

For more than a decade, artificial intelligence has been touted as a way to dramatically accelerate drug discovery . Yet despite billions of dollars in investment, relatively few AI-designed medicines have made it to patients. That’s partially because the timelines for careful drug testing can’t be easily compressed—and partially because drug development is just really hard. Isomorphic Labs , the Google DeepMind spin-off that’s building on DeepMind’s Nobel Prize-winning work on protein structure prediction , may be making the most progress. The company has signed major drug-discovery partnerships with Novartis and Eli Lilly and recently raised US $2.1 billion in funding . In February, it published a technical report describing its new Isomorphic Drug Design Engine, a system created to discover the “pockets” on proteins where drugs can bind and in general to predict how proteins and drug molecules interact. IEEE Spectrum spoke with Adrian Stecuła , a group leader in the machine learning organization at Isomorphic Labs, about how close AI may be to becoming a practical tool for designing new medicines. Going Beyond AlphaFold AlphaFold2 and AlphaFold3 were massive leaps forward for computational biology. Why weren’t those models sufficient for actually designing drugs? Adrian Stecuła: AlphaFold2 was eventually recognized with the Nobel Prize , because it arguably solved the problem of protein folding. But proteins don’t exist in a vacuum, right? They interact with a wide variet…

Demis Hassabis On What AI Will Do Next

Thank you to Google DeepMind for the invite. 🙏 ❤️ Check out Lambda here and sign up for their GPU Cloud: https://lambda.ai/papers Our Patreon if you wish to support us: https://www.patreon.com/TwoMinutePapers 🙏 We would like to thank our generous Patreon supporters who make Two Minute Papers possible: Adam Bridges, Benji Rabhan, B Shang, Cameron Navor, Charles Ian Norman Venn, Christian Ahlin, Eric T, Fred R, Gordon Child, Juan Benet, Michael Tedder, Owen Skarpness, Richard Sundvall, Ryan Stankye, Shawn Becker, Steef, Taras Bobrovytsky, Tazaur Sagenclaw, Tybie Fitzhugh, Ueli Gallizzi My research: https://cg.tuwien.ac.at/~zsolnai/ Thumbnail design: https://felicia.hu 00:00 Intro 00:40 Gemini Health Scans and Gemma 4 01:30 AI as a Brainstorming Partner 02:30 Second Order Nobel 03:15 DeepMind Co-Scientist 05:00 Curing All Diseases 06:30 Exponential Growth in Drug Discovery 07:45 Regulatory Bottlenecks 09:45 Accelerating Clinical Trials 11:15 EVE Online Partnership 13:15 The Einstein Test 15:30 Recursive Self-Improvement 18:15 Lightning Round 19:30 The Badge of Honor 20:10 Behind the Scenes

How Sunny Health Built an AI Healthcare Concierge with Qdrant

Most people don’t read their insurance pamphlet. The benefits are there: deductibles, copays, in-network providers, what dental covers, what dermatology covers, when an optometry visit is included in the medical plan. But the document is dense, the website is worse, and the result is that patients pay for plans they barely understand and delay care because finding an in-network provider with availability takes more energy than they have. Sunny Health is building a healthcare concierge that insurance companies and care providers offer to their members as part of the existing plan experience. When a member signs in (typically through SSO from their payer), Sunny Health already knows who they are and what their plan covers. They land in a chat experience where they can ask “show me dermatologists nearby,” get matched to in-network options, and have Sunny Health book the appointment on their behalf. Three things on one retrieval layer: benefits navigation, provider matching, and appointment booking.

Intelligence is collective, not artificial — Prof. Michael I. Jordan (UC Berkeley / Inria)

Michael I. Jordan, described by Science magazine as the most influential computer scientist alive, has never thought of himself as an AI researcher. In this conversation he explains why that distinction matters. SPONSOR: --- Cyber Fund built the Monastery to help founders ship products that were impossible a year ago. Applications for Batch 1 are now open. Apply now: https://cyber.fund --- Jordan trained as a statistician and cognitive scientist, and his career has been spent building machine learning systems that work in the real world: supply chains, commerce, healthcare, and large economic systems. When the field rebranded itself as AI and then AGI, he did not follow. Instead he argues that the framing is wrong. AI is better understood as a collective economic system than as a race to build a disembodied superintelligence. We talk about why AGI is mostly a PR term, what machine learning achieved before the LLM hype cycle, and why the assistant-on-your-shoulder vision may be less compelling than it sounds. Jordan explains why explanations need to be actionable, not merely mechanistic; why AlphaFold's missing error bars matter; how prediction-powered inference changes the picture; and why drug discovery is an incentive-design problem rather than a pure pattern-matching problem. ERRATA: Science magazine ranked him the most influential computer scientist, not Nature --- TIMESTAMPS: 00:00:00 Cold open: A demoralizing message to young builders 00:02:04 CyberFund sponsor read 00…

OpenEvidence Powers Medical AI with Zilliz Cloud

ByteDance spins out drug discovery unit to test AI4S commercialization